Shenzhen Glory Medical Co Ltd

Glory Medical released its 2026 interim report. First-half operating revenue was 566 million yuan, up 7.1 percent year on year, but net profit attributable to the parent swung from a loss of 7.76 million yuan a year earlier to a loss of 15.64 million yuan. Net profit attributable to the parent after deducting non-recurring items widened from a loss of 12.52 million yuan to a loss of 23.28 million yuan, and net operating cash flow was negative 15.72 million yuan, down 894.3 percent year on year. Second-quarter operating revenue was 308 million yuan, up 24.2 percent year on year, while the net loss attributable to the parent was 13.84 million yuan, narrowing from a loss of 21.72 million yuan in the same period last year. As of the end of the second quarter, the company's total assets were 3.221 billion yuan, down 3.3 percent from the end of the previous year, and net assets attributable to the parent were 2.456 billion yuan, down 1.1 percent from the end of the previous year.

Shangrong Medical has released its 2026 half-year performance forecast, projecting a net loss attributable to shareholders of 11 million to 16 million yuan for the first half, compared with a loss of 7.7582 million yuan in the same period last year. The company stated that customer collections during the reporting period were weaker than a year earlier, and as receivables aged, credit impairment losses rose significantly year-on-year, widening the loss.